SCHEMBL19782076

SCHEMBL19782076

Cc1cccc(C=N)c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.56
TRPA1 O75762 2/20 0.50
GABRA1 P14867 1/20 0.43
GABRB2 P47870 1/20 0.43
PTGER1 P34995 1/20 0.43
PTGER4 P35408 1/20 0.43
PTGER3 P43115 1/20 0.43
PTGER2 P43116 1/20 0.43
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
KDM4E B2RXH2 5/20 0.42
HPGD P15428 3/20 0.42
HSD17B10 Q99714 2/20 0.42
MAPT P10636 3/20 0.41
GAA P10253 3/20 0.41
POLB P06746 2/20 0.41
HTT P42858 2/20 0.41
MPI P34949 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL172956 0.77 ERN1 (0.61) ALDH1A1TRPA1GABRA1GABRB2PTGER1
SCHEMBL5073330 0.77 ALDH1A1 (0.56) ALDH1A1TRPA1GABRA1GABRB2PTGER1
SCHEMBL29957719 0.77 ERN1 (0.61) ALDH1A1TRPA1GABRA1GABRB2PTGER1
SCHEMBL598777 0.77 ALDH1A1 (0.56) ALDH1A1TRPA1GABRA1GABRB2PTGER1
SCHEMBL14899338 0.76 ERN1 (0.60) ALDH1A1TRPA1CA1CA2KDM4E
SCHEMBL5090901 0.76 GABRA1 (0.43) ALDH1A1GABRA1GABRB2CA1CA2
SCHEMBL7114535 0.76 TRPA1 (0.42) ALDH1A1TRPA1CA1CA2CA9
SCHEMBL20339223 0.76 ERN1 (0.59) ALDH1A1TRPA1GABRA1GABRB2PTGER1
SCHEMBL2158535 0.76 ALDH1A1 (0.54) ALDH1A1TRPA1GABRA1GABRB2PTGER1
SCHEMBL2158538 0.76 ALDH1A1 (0.54) ALDH1A1TRPA1GABRA1GABRB2PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171492-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-06-10 US disclosed
US-10351547-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2019-07-16 US disclosed
US-20190002431-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2019-01-03 US disclosed
US-9896432-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2018-02-20 US disclosed
WO-2018013676-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10351547-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 ALDH1A1 4626/4885TRPA1 1736/4885GABRA1 322/4885
US-20190002431-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 ALDH1A1 4626/4885TRPA1 1736/4885GABRA1 322/4885
US-20210171492-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 ALDH1A1 4626/4885TRPA1 1736/4885GABRA1 322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.